TC BioPharm (Holdings) plc - American Depositary Shares (TCBP)

As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

TC BioPharm said its securities will be suspended for trading on the exchange beginning Monday.

TC Biopharm shares are trading lower by 64% during Friday's session. The company announced the transition from Nasdaq to OTC markets.

Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues, with data expected in 2025.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

TC BioPharm to issue a special dividend of 0.25 ADS per share, pending shareholder approval at the December 30 meeting. Record date: January 2, 2025.